Clinical Comparative Analysis Of The Efficacy Of Tegafur/nedaplatin-Based With Fluorouracil/cisplatin-based Concurrent Chemoradio-Therapy In The Treatment Of Non-surgical Esophageal Squamous Cell Carcinoma

Objective:To compare the efficacy and adverse reactions of tegafur/nedaplatin-based with fluorouracil/cisplatin-based concurrent chemoradiotherapy in the treatment of non-surgical esophageal squamous cell carcinoma.Methods : We retrospectively collected non-surgical esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy in the radiotherapy department of Liaoning Provincial Cancer Hospital(China Medical University Cancer Hospital)from 2011.1.1 to 2015.12.31.A total of 112 patients were divided into group A(Tegafur combined with nedaplatin concurrent chemoradiotherapy)and group B(fluorouracil combined with cisplatin concurrent chemoradiotherapy)according to different chemotherapy regimens.The short-term efficacy,1,2,and 3 years survival rates and adverse reactions were compared between the two groups.Results:The objective response rate(ORR)of group A was 77.78%,and the disease control rate(DCR)was 90.74%,and 60.34% and 75.86% in the group B,respectively,there were significant differences in RR(P<0.05)and DCR(P<0.05)between the two groups.The 1-year,2-year,and 3-year survival rates of group A were 92.59%,62.96%,and 35.19%,and 87.93%,43.10% and 17.24% in the group B,respectively.There was no significant difference in 1-year survival rate between the two groups(P>0.05),but the 2-year and 3-year survival rates of group A were significantly higher than those of group B(P<0.05).After analyzing the overall survival curves of the two groups,the median survival time of group A was 31 months,and the median survival time of group B was 23 months,suggesting that group A(tegafur+nedaplatin)significantly improved the overall survival of patients compared with group B(fluorouracil + cisplatin)(P<0.05).In terms of adverse reactions,there were no significant differences in the incidence of radiation esophagitis,radiation pneumonitis,myelosuppression,and esophageal stricture between the two groups(P>0.05),but the incidence of gastrointes-tinal reactions in group A was lower than that in group B,with a statistically signifi-cant difference(P<0.05).Conclusions:Compared with fluorouracil/cisplatin-based concurrent chemoradio-therapy,tegafur/nedaplatin-based concurrent chemoradiotherapy in the treatment of non-surgical esophageal squamous cell carcinoma showed better short-term efficacy and fewer adverse reactions,which can improve the patients' survival.This treatment is safe and feasible,and it is worthy of verification by large sample randomized con troll-ed trials.